Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 4.0x - 4.5x | 4.2x |
| Historical Pb Multiple | 2.8x - 6.2x | 4.1x |
| Fair Value | €53.08 - €58.67 | €55.88 |
| Upside | -8.5% - 1.2% | -3.7% |
| Benchmarks | - | Full Ticker |
| Revvity, Inc. | - | DB:PKN |
| Pharmaron Beijing Co., Ltd. | - | DB:17Q1 |
| Eurofins Scientific SE | - | ENXTPA:ERF |
| Agilent Technologies, Inc. | - | DB:AG8 |
| Sartorius Aktiengesellschaft | - | DB:SRT |
| Lonza Group AG | - | DB:LO3A |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| PKN | 17Q1 | ERF | AG8 | SRT | LO3A | |||
| DB:PKN | DB:17Q1 | ENXTPA:ERF | DB:AG8 | DB:SRT | DB:LO3A | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 4.4% | 26.8% | 19.6% | 3.8% | -11.7% | -0.3% | ||
| 3Y CAGR | -31.7% | 2.6% | -21.9% | 2.1% | -35.9% | -1.9% | ||
| Latest Twelve Months | 41.2% | 26.0% | 16.9% | -6.1% | 32.8% | 27.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 19.1% | 17.1% | 8.3% | 17.9% | 12.0% | 22.4% | ||
| Prior Fiscal Year | 6.5% | 13.9% | 3.9% | 18.1% | 6.1% | 9.7% | ||
| Latest Fiscal Year | 10.3% | 14.6% | 5.1% | 19.8% | 2.5% | 9.7% | ||
| Latest Twelve Months | 10.0% | 14.7% | 5.3% | 17.6% | 3.0% | 10.3% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 10.3% | 15.0% | 11.5% | 21.4% | 21.2% | 8.7% | ||
| Prior Fiscal Year | 2.4% | 13.9% | 5.2% | 22.2% | 10.1% | 6.5% | ||
| Latest Twelve Months | 3.6% | 14.0% | 7.7% | 18.9% | 3.9% | 8.2% | ||
| Next Fiscal Year | 7.6% | 12.8% | 14.0% | 26.8% | 11.5% | 12.6% | ||
| Two Fiscal Years Forward | 8.5% | 14.2% | 16.6% | 28.2% | 12.8% | 14.2% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 3.7x | 3.7x | 1.7x | 4.9x | 3.3x | 5.4x | ||
| Price / LTM EPS | 36.7x | 25.4x | 31.0x | 27.9x | 109.5x | 52.5x | ||
| Price / Book | 1.4x | 3.4x | 2.5x | 5.3x | 4.3x | 4.5x | ||
| Price / Fwd Book | 1.4x | 4.3x | 2.4x | 5.4x | 3.8x | 4.0x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 1.4x | 3.4x | 5.3x | |||||
| Historical P/B Ratio | 2.8x | 4.1x | 6.2x | |||||
| Selected P/B Multiple | 4.0x | 4.2x | 4.5x | |||||
| (x) Book Value | 8,621 | 8,621 | 8,621 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | PKN | 17Q1 | ERF | AG8 | SRT | LO3A | |
| Value of Common Equity | 10,067 | 62,243 | 11,809 | 32,345 | 11,480 | 37,989 | |
| (/) Shares Outstanding | 117.9 | 3,235.4 | 177.7 | 284.1 | 77.9 | 696.0 | |
| Implied Stock Price | 85.41 | 19.24 | 66.46 | 113.87 | 147.40 | 54.58 | |
| FX Conversion Rate to Trading Currency | 1.16 | 8.36 | 1.00 | 1.16 | 1.00 | 0.94 | |
| Implied Stock Price (Trading Cur) | 73.36 | 2.30 | 66.46 | 97.80 | 147.40 | 58.00 | |
| Trading Currency | EUR | EUR | EUR | EUR | EUR | EUR | |
| FX Rate to Reporting Currency | 1.16 | 8.36 | 1.00 | 1.16 | 1.00 | 0.94 | |